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Background 
Polypropylene meshes cause severe complications in some patients.  Materials that are 
biomechanically compatible and can better integrate into host tissues are urgently needed. 
Objective 
To design an estradiol-releasing electrospun poly-L-lactic acid (PLA) scaffold and evaluate its 
ability to stimulate new extracellular matrix and new blood vessel formation.  
Design, setting and participants 
Human adipose derived mesenchymal cells (ADMSC) were from fat tissue.  Electrospun PLA 
scaffolds containing 1%, 5% and 10% estradiol were constructed.  and used for in vitro and 
in vivo experiments.  
Interventions 
The angiogenic potential of the scaffolds was evaluated using an ex ovo chorioallantoic 
membrane (CAM)  and chick aortic arch assays.  
Measurements 
Estradiol release was measured fluorimetrically.  The effect of scaffolds on proliferation and 
extracellular matrix (ECM) production of ADMSC was assessed by immunohistology.  
Mechanical properties were tested using a tensiometer.  
Results and limitations 
Scaffold structure was not affected by the inclusion of estradiol and mechanical properties 
were only slightly modified.  Estradiol was released from PLA scaffolds over a 5-month 
period. ADMSCs cultured on estradiol-releasing PLA scaffolds produced more ECM involving 
collagen I, III and elastin.  Estradiol-releasing scaffolds doubled  new blood vessel formation 
in the CAM assay (p= 0.001) and outgrowth of pro-angiogenic cells in the aortic arch assay 
(p= 0.001).  Further in vivo studies in higher animal models are required. 
Conclusion 
Estradiol releasing PLA scaffolds increase ECM production and stimulate angiogenesis. As 
such, they are promising candidate materials to be used in pelvic floor repair and to improve 
the initial healing phase of a repair material following implantation.   
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Patient summary 
In this study we designed a tissue engineered material that can be used to support 
weakened pelvic floor tissues in women avoiding the complications associated with current 
surgical mesh. Our results showed that this material can integrate well into tissues by 
stimulating new blood vessel formation.    
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1. Introduction 
In the 1990s, Petros et al reported  the implantation of PPL mesh tapes to treat stress 
urinary incontinence (SUI) 1. Following this, larger areas of mesh were used to repair pelvic 
organ prolapse (POP), however, serious complications have now been demonstrated  in up 
to 15% of women  2 and to a lesser degree in SUI surgery 3.  In 2016, the US Food and Drug 
Administration (FDA) re-classified trans-vaginal mesh devices from class II to III 4. This led to 
a reduction in the number of trans-vaginal mesh surgeries performed for POP from 27% to 
2% 5, with a more modest decline in the number of mid-urethral tapes inserted 6. It appears 
that we are now back to a pre- mesh era with some important lessons to be learned.   
PPL devices evolved over many years from an initial metal wire mesh 7 to the current 
monofilament, macroporous mesh used in contemporary practice 8.  PPL mesh was not 
designed evaluated for safety in the pelvic floor prior to its introduction.  The mechanical 
properties, microbial flora and vascularization status of paravaginal tissues are very 
different to that of the abdomen. Recent data has demonstrated site-specific responses to 
implanted PPL mesh; contraction and exposure of the mesh occurred following trans-vaginal 
implantation in sheep, while no complications were demonstrated following  abdominal 
implantation over 12 months 9.  Furthermore, PPL mesh undergoes an M1 
(proinflammatory) macrophage response, characterized by expression of pro-inflammatory 
cytokines, which leads to a vigorous foreign body reaction 10. 
Materials that are specifically designed for implantation into the pelvic floor are urgently 
required 11.  In exploring several candidate materials, we identified electrospun poly-L-lactic 
acid (PLA) scaffolds as a material, which possess mechanical properties more closely related 
to those of healthy paravaginal tissues 12 and it induces an M2 macrophage response 
associated with constructive remodelling 10.  Electrospun PLA may therefore lead to better 
integration during the initial healing phase following implantation, whilst providing 
appropriate structural support for tissues.   
A well vascularized wound bed is crucial to achieve rapid integration of materials following 
implantation. Clinical studies report a decrease in vaginal blood flow in postmenopausal 
women, which improves significantly after estrogen replacement 13. 17-ɴĞstradiol plays a 
vital role in maintenance of normal structure and function of pelvic tissues. It is an inhibitor 
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of matrix metalloproteinases 14 and stimulates neo-collagen synthesis 15 and directly 
stimulates vascular endothelial cells through the estrogen receptor 16.  
A potential solution to improving the angiogenic potential of repair devices is to incorporate 
pro-angiogenic drugs into materials 17. The aim of this study was to develop an estradiol-
releasing electrospun mesh of PLA  and evaluate its ability to support cell proliferation, and 
stimulate neovascularization to improve the integration of materials into the wound bed 
suitable for urogynaecological applications.     
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2. Materials and Methods 
2.1. Electrospinning 
Poly-L-lactic acid (Goodfellow, Cambridge, UK) at 10% (wt/v) was dissolved in 
dichloromethane.  17-ɴĞƐƚƌĂĚŝŽů ?^ŝŐŵĂ-Aldrich) was added  at 1%, 5% and 10% by mass of 
polymer.  20mls of polymer solutions were loaded into syringes fitted with 21G needles, 
placed into a syringe pump (GenieTMPlus, Kent Scientific, USA), and delivered at 40ʅů ?ŵŝŶ
per syringe.  Random microfibres were created at an accelerating voltage of 17kV DC and 
collected on an aluminium foil covered earthed mandrel rotating at 300rpm. 
2.2. Scanning Electron Microscopy (SEM) 
Samples were mounted on 12.5mm stubs and sputter coated with 25nm of gold (Edwards 
sputter coater S150B, Crawley, England).  SEM (Philips/FEI XL-20 SEM; Cambridge, UK) was 
performed at an accelerating voltage of between 10-15 kV and a SPOT size between 2 and 3. 
Fibre diameter and pore size were measured using ImageJ software (National Institute of 
Health) 18.   
2.3. Release of estradiol from scaffolds 
Scaffolds were cut to 15mm2, weighed and incubated in 1ml/well of Phosphate buffered 
saline (PBS).  The estradiol concentration released from each of the 3 scaffold groups (10mg 
(1% wt/vol), 50mg (5% wt/vol) and 100mg (10% wt/vol)) over 5 months was measured 
fluorimetrically (Kontron SFM 25 spectrofluorimeter) Ăƚʄex ? ? ?Ŷŵ ?ʄem310nm against 
solutions of known concentration (n=6 per group).  Fresh PBS was replaced after each 
sample was removed.   
2.4. Culture of Adipose-derived mesenchymal stem cells (ADMSC) on scaffolds  
ADMSC were  cultured from human subcutaneous fat as described previously 12, donated 
under an HTA research tissue bank license (08/H1308/39).  Cells were cultured in ƵůďĞĐĐŽ ?Ɛ
Modified Eagles medium (DMEM) supplemented with 10% (v/v) fetal calf serum (FCS) 
(Advanced Protein Products, Brierley Hill, UK) ? ?ŵDŐůƵƚĂŵŝŶĞ ? ? ? ? ? ?ʅŐ ?ŵ>ĂŵƉŚŽƚĞƌŝĐŝŶ ?
100IU/mL peŶŝĐŝůůŝŶĂŶĚ ? ? ?ʅŐ ?ŵ>ƐƚƌĞƉƚŽŵǇĐŝŶ(Gibco Invitrogen, Paisley, UK).  
Scaffolds were cut to 15mm2 and sterilized in 70% ethanol.  500,000 passage 3 ADMSC were 
seeded per scaffold and samples cultured for 2 weeks at 37oC, 5% CO2. The metabolic 
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activity of seeded ĐĞůůƐǁĂƐƋƵĂŶƚŝĨŝĞĚďǇůĂŵĂƌůƵĞ ?(Sigma-Aldrich, Dorset, UK) assay at 
days 7 and 14, as described previously 18.   
2.5. Assessment of ability of ADMSC to proliferate and produce extracellular matrix on estradiol 
releasing scaffolds  
Samples were fixed with paraformaldehyde after 2 weeks of culture and stained with 1ml of 
 ?ŶŐ ?ŵůŽĨ ?഻ ? ?-diamidino-2-phenylindole dihydrochloride ((DAPI) Gibco Invitrogen, Paisley, 
UK).  After incubating with bovine serum antigen, primary antibodies were added, including 
goat anti-human collagen I, III and rabbit anti-human alpha elastin (AbD Serotec, Oxford, 
UK).  100µl of 1:20 primary and 100µl of 1:50 secondary antibodies were added, including 
FITC labelled anti-goat IgG and anti-rabbit IgG.   
 DAPI stained nuclei and FITC labelled matrix components  were imaged using a fluorescent 
microscope (Axon ImageXpressTM, Molecular Devices Limited, Union City, CA) by switching 
between filters foƌW/ ?ʄex ? ? ?Ŷŵ ?ʄem ? ? ?Ŷŵ ?ĂŶĚ&/d ?ʄex ? ? ?Ŷŵ ?ʄem515nm).   
Total collagen production was measured by Sirius Red staining as described previously using  
0.1% solution of Sirius Red F3B in saturated picric acid 18.    
2.6.   Assessment of effects of estradiol on differentiation capacity of ADMSC 
ADMSCs at passage 3 were cultured with 15mm2, weight matched sections of either 
estradiol-releasing or control PLA scaffolds in DMEM (n=6).  After 24 hours , media was 
replaced with specific induction medium and cultured for 3 weeks.  Adipogenic and 
osteogenic induction media contained the following supplements in addition to above 
defined DMEM:  1 µM dexamethasone, 0.5 mM methyl-isobutylxanthine, 10 µg/mL insulin 
and l00 µM indomethacin for adipogenic media and 10 nM dexamethasone, 50 µg/mL 
ascorbate-2-phosphate and 2 mM b-glycerophosphate for osteogenic media.   
Cells were fixed and stained with Oil Red O and Alizarin Red for adipogenic and osteogenic 
phenotypes, respectively. Counter staining was performed using haematoxylin.  Histological 
differences were assessed blindly by 6  post-doctoral researchers.  All reagents were from  
Sigma-Aldrich, Dorset, UK.  
2.7. Assessment of effect of estradiol on mechanical properties of scaffolds 
Scaffolds were cut into 5mm x 10mm sections and clamped into a tensiometer (BOSE 
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Electroforce Test Instruments, MN) using a 22N load cell and a ramp test at a rate of 
0.1mm/sec. Results were standardized by width and thickness of materials (N/mm2).  Tests 
were performed both before and after 7 days of ADMSC culture on the scaffolds.   
The initial linear gradient of each resulting stress vs strain ĐƵƌǀĞǁĂƐƚĂŬĞŶĂƐƚŚĞzŽƵŶŐ ?Ɛ
modulus (N/mm2), while the ultimate tensile strength (UTS) was taken as the force per area 
of sample at break/maximal point.  Both values were compared to data published for 
paravaginal tissues of healthy premenopausal patients 19.   
2.8. Assessment of angiogenic potential  of estrogen releasing scaffolds  
Angiogenesis was assessed using an ex ovo chick chorionic allantoic membrane (CAM) and 
an in vitro chick aortic arch assay.  Pathogen-free fertilized white leghorn chicken eggs 
(Gallus gallus domesticus) were obtained from Henry Stewart Co. (UK). Care was consistent 
with the Home Office, UK guidelines. Embryos were cultured using an ex ovo (shell less) 
method 20. Embryos were transferred into a petri dish on embryonic development day (EDD) 
3 and maintained in a humidified incubator at 38°C between EDDs 3 to 14. Embryo survival 
was assessed daily.  
The ex ovo CAM assay 
Scaffolds were cut into 6.5mm diameter circles using an Epilog Laser Cutter (Clevedon, UK) 
and sterilized under UV light. At EDD 8, two scaffolds were placed on the CAM surface.  At 
EDD 14, images of scaffolds and surrounding CAM area were taken with a digital 
microscope. After imaging, 0.1mL of a 20% solution of Lens culinaris agglutinin [LCA (Vector 
Laboratories)] was injected into the circulation using a 30G hypodermic needle to 
fluorescently label intraluminal endothelial cells. Embryos were sacrificed and scaffolds 
were removed from the CAM surface .  Angiogenesis was quantified by counting all 
discernible blood vessels traversing a 1mm annulus about the 2mm imaginary circle drawn 
around the scaffold 21.   
Chick aortic assay 
Embryos were sacrificed on EDD 14, the aortic arch removed and cut into 1mm rings under 
a stereomicroscope.  Aortic rings were embedded in 50µL of Matrigel® (Basement 
Membrane Matrix, Corning®) and cultured in Minimum Essentials Media supplemented with 
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 ? ? ?A?&^ ? ? ?ƵŶŝƚƐ ?ŵ>ƉĞŶŝĐŝůůŝŶĂŶĚ ? ?ʅŐ ?ŵ>ƐƚƌĞƉƚŽŵǇĐŝŶ (GIBCO, Carlsbad, CA). Rings 
were co-cultured with scaffolds using an insert (Greiner Bio-One GmbH).  Endothelial sprout 
length was observed under an inverted microscope from day 5. Endothelial cells were 
characterized by immunofluorescence staining with Isolectin B4 (Vector Laboratories, 
Burlingame, USA).    
2.9. Histology  
Scaffolds and surrounding CAM were fixed with paraformaldehyde, and embedded in 
freezing medium. 6µM sections were taken using a cryostat (Leica CM1860UV, Leica, 
Germany). Slides were stained with DAPI and observed under an epifluorescence 
microscope (Olympus, Japan).   
2.10. Statistics 
 Statistical differences between two group means were analysed using  Student ?Ɛ T test 
when the data was normally distributed and with Mann Whitney U test otherwise. Survival 
of the chick embryos were analysed with the Kaplan Meier method.  A p value of <0.05 was 
considered statistically significant.    
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3. Results 
3.1. Effect  of estradiol on scaffold ultrastructure  
There was no significant difference between the fibre diameter and pore size of PLA versus 
estradiol-releasing PLA scaffolds (0.65±0.30 µm vs 0.71±0.28 µm [p=0.47] and 4.26±2.29 µm 
vs 4.25±2.04 µm [p= 0.98], respectively) as shown in Figure 1 
3.2. Release of estradiol from scaffolds over 5 months 
The cumulative release of estradiol increased for each time-point, until no further estradiol 
was released as demonstrated in Figure 2.  The total estradiol released from the scaffolds 
was equivalent to 2.5%, 1.4% and 2.45% of the initial estradiol present in the polymer 
solution for the 10mg, 50mg and 100mg estradiol scaffolds, respectively. A burst release 
between 40- 50% of the drug was observed in the first 14 days.   
3.3. Effect of estradiol releasing scaffolds on differentiation capacity of ADMSC 
Culturing ADMSC in specific induction media resulted in cellular differentiation over 3 
weeks, including the formation of lipid vesicles for ADMSC cultured in adipogenic medium 
and the presence of calcium for cells cultured in osteogenic medium (Figure 3).  There were 
no significant differences in cell morphology, lipid vesicles or calcium content between 
control and estradiol-releasing scaffolds, as assessed using blind scoring.   
3.4. Effect of estradiol on metabolic activity and extracellular matrix production of ADMSCs  
Figure 4a demonstrates an increase in metabolic activity from 7 to 14 days for cells cultured 
on both estradiol and control scaffolds, with a greater increase seen for cells cultured on 
estradiol scaffolds (p<0.01).  ADMSCs cultured on estradiol scaffolds for 14 days produced a 
greater proportion of collagen than cells cultured on control scaffolds (p<0.001) as 
demonstrated in Figure 4b.  Figure 4c  shows a greater proportion of collagen  I and III and 
elastin from culture of ADMSC on estradiol scaffolds compared to controls.    
3.5. Effect of estradiol on the mechanical properties of scaffolds 
Figure 5a demonstrates that estradiol-ƌĞůĞĂƐŝŶŐƐĐĂĨĨŽůĚƐƐŚŽǁĂzŽƵŶŐ ?ƐDŽĚƵůƵƐĐůŽƐĞƌƚŽ 
the values of healthy native fascia. After 2 weeks of cell culture, both scaffolds become 
more elastic, however estradiol-releasing scaffolds were significantly stiffer (p<0.01) than 
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control scaffolds. Figure 5b demonstrates that estradiol-releasing scaffolds are significantly 
stronger than controls, both before and after 2 weeks of cell culture.  Of note, the UTS of 
control scaffolds decreases after 14 days of cell culture, while the UTS of estradiol-releasing 
scaffolds increases. 
3.6.  Effect of estradiol on the angiogenic properties of PLA scaffolds 
The CAM assay demonstrates at least double the number of blood vessels growing towards 
the estradiol scaffolds compared to controls over 7 days (mean vessel count: 25.0 (±5.29) 
and 10.67 (±2.64) respectively, p<0.001 as shown in Figure 6A and B).  Estradiol did not 
affect embryo survival rates (Figure 6C).    
Estradiol-releasing PLA scaffolds induced longer and denser endothelial sprouts when co-
cultured with chick aortic rings (Figure 7A).  Figure 7C demonstrates a sprout length/radius 
of 1.6 (±0.51) and 1.0 (±0.44) for estradiol-releasing and control scaffolds respectively 
(p=0.01) (Figure 7C).   
Host tissues infiltrated into each scaffold to a similar degree (Figure 8).  There was an 
increased number of blood vessels (stained with fluorescent angiography) in the CAM tissue 
adjacent to and in- between the fibres of the estradiol-releasing scaffolds compared to 
controls.   
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4. Discussion 
Biodegradable repair materials should ŝŶƚĞŐƌĂƚĞǁĞůůŝŶƚŽƚŚĞƉĂƚŝĞŶƚ ?ƐƚŝƐƐƵĞƐ and be strong 
enough to provide structural support, while regeneration of host tissues over time 
eventually assumes this load bearing function.  
In this study we demonstrate that incorporation of estradiol into the fibres of an 
electrospun PLA scaffold do not significantly alter the overall microstructure and mechanical 
properties of the scaffold. Tissue integration was assessed in this study through the 
interaction cells in vitro with the scaffold and the ability of the scaffold to stimulate 
angiogenesis in vivo. For the former, ADMSC were selected as a representative cell source, 
capable of undertaking a range of phenotypes.  Estradiol was released over a five-month 
period in a dose-dependent manner. Scaffolds consisted of random micro-fibres with a 
range of pore sizes up to 10µm. While porosity influences the ease of cell infiltration into 
the scaffold, our previous studies with electrospun PLA implanted in rats 22 and rabbits 10 
demonstrates a rapid integration of host tissues with an M2 macrophage (tissue 
remodelling) response.  
Several assessments of non-degradable polypropylene meshes in dogs 23, sheep 9, rhesus 
macaque 24 and humans 25 demonstrate sustained chronic inflammation. Biodegradable PLA 
meshes last intact for at least one year when implanted in rat models 22. In the current study 
we demonstrate that inclusion of estradiol improved the ability of ADMSCs to stimulate new 
ECM production including collagen I, III and elastin. 
The most critical feature of this estradiol-releasing PLA scaffold is the significant increase 
seen in the number and density of blood vessels and integration of tissues into this material 
when implanted into the CAM assay.  The CAM assay is an established method for the in 
vivo evaluation of angiogenesis, which allows direct visualization of the newly forming 
vessels into a biomaterial 26.   
An estradiol releasing electrospun scaffold has previously been described for use as a 
wound care product in post-menopausal women, where the anti-inflammatory properties of 
estradiol were utilized 27. Estradiol has  been demonstrated to stimulate endothelial cells to 
produce VEGF when released from a collagen based scaffold 28. Here we demonstrate for 
the first time that estradiol released from an electrospun scaffold dramatically stimulates 
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new blood vessel formation in and around the material.  Although we have designed this 
material for use in pelvic floor repair, it could have wider applications in all areas of tissue 
engineering as a pro-angiogenic scaffold.    
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Surgical mesh used in pelvic floor is associated severe complications in some patients.  There 
is an unmet and urgent need for better materials.  Tissue engineered scaffolds that can 
better integrate into host tissues can be designed making use of estradiol.  
*Take Home Message
Figures 
 
 
Figure 1. Representative images of scaffolds under SEM. Histograms on the right demonstrate distribution 
of fibre diameters and pore sizes in both scaffolds. Scale bars represent 10 µm. 
Illustration
 Figure 2. Cumulative release of estradiol from 3 different estradiol releasing scaffolds over 133 days 
as measured using a spectrofluorometer (n=6±SEM). 
 
Figure 3.  Differentiation assays.  ADSC cultured either in DMEM, adipogenic media or osteogenic 
media, stained with haematoxylin and Oil red O (for lipid vesicles) or Alizarin red (for calcium).  Scale 
bar represents 50µm.   
 Figure 4.  Extracellular matrix production by ADSC cultured on Estradiol releasing PLA scaffolds 
compared to PLA only scaffolds. (A) Cell metabolic activity of ADSC cultured on control and estradiol 
releasing PLA scaffolds as measured by AlamarBlue assay with absorbance measured at 570nm using 
plate reading colourimeter.  (n=6 ±SEM). **p<0.01. (B)  Total collagen production at day 14 as 
measured by Sirius red assay with absorbance measured at 490nm using plate reading colourimeter.  
(n=6 ±SEM). ***p<0.001. (C) Fluorescent microscopy images of extracellular matrix components 
produced by ADSC after 14 days of culture.  Collagen I (green), elastin (red) and cells (blue).  Scale bar 
represents 100µm.   
 
 
  
 
Figure 5.  The effect of oestradiol on the strength of the scaffolds assessed in the presence of 
ADMSCs. 
 ?zŽƵŶŐ ?ƐDŽĚƵůƵƐŽĨĐŽŶƚƌŽůĂŶĚĞƐƚƌĂĚŝŽůƌĞůĞĂƐŝŶŐW>ƐĐĂĨĨŽůĚƐ, before and after 14 days of cell 
culture with ADSC.  Area between dashed lines represents values for healthy native fascia [18].  
N=6±SEM, **p<0.01.   
A 
B 
B.  Ultimate Tensile Strength of control and estradiol releasing PLA scaffolds, before and after 14 days 
of cell culture with ADSC.  The area between the dashed lines represents values for healthy native 
fascia [18].  N=6±SEM, ***p<0.001.   
 
 
Figure 6.  Angiogenic potential of estradiol releasing PLA scaffolds compared to PLA only scaffolds, 
day 14 on chicken chorioallantoic membrane (CAM) assay. A normal distribution of blood vessels was 
observed when the control PLA scaffold was placed on the CAM. With the estradiol releasing scaffold 
newly formed blood vessels can be seen to radiate towards the scaffold in a spoke- wheel pattern (A). 
The mean vessel count of estradiol releasing scaffolds was double that of the PLA scaffolds (B) and 
the embryo survival rate was the same between the two groups (C).   (Scale bars represent 3mm). 
 Figure 7.  A)  Evaluation of effect of estradiol on endothelial cell proliferation and sprouting. One 
millimetre rings from the chick aorta were embedded in Matrigel and co- cultured with PLA only 
scaffolds (upper row) or Estradiol releasing PLA scaffolds   (lower row). The extent of endothelial 
sprouting by 5 days in culture is much greater in the presence of estradiol. B) Fluorescent microscopy 
images of immunological staining.  Lectin IB4 - endothelial cells stained green, nuclear components 
stained blue (DAPI).  C) Sprout length/radius results taken from 11A, * P=0.01.  (Sjnnncale bars 
represent 50 µm). 
 
 
  
Figure 8. A mild inflammatory reaction  together with a normal distribution of blood vessels on the 
CAM adjacent to the PLA scaffold (upper raw) can be observed compared to a significantly increased 
number of large blood vessels in response to Estradiol releasing PLA scaffold (lower raw) at day 14, 
Haematoxylen &Eosin (H&E) staining (left side). Also on higher magnification several small blood 
vessels could be observed in between the PLA fibers which was more abundant in the presence of 
Estradiol (middle). On the right endothelial cells lining all sizes of blood vessels appear stained 
Rhodamine- conjugated Lens culinaris agglutinin and cell nuclei are stained with DAPI.  Scale bars 
represent 100 µm. 
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Background 
Polypropylene meshes cause severe complications in some patients.  Materials that are 
biomechanically compatible and can better integrate into host tissues are urgently needed. 
Objective 
To design an estradiol-releasing electrospun  poly-L-lactic acid (PLA) mesh and evaluate its 
ability to stimulate new extracellular matrix and new blood vessel formation. 
Design, setting and participants 
Human adipose derived mesenchymal cells (ADMSC) were isolated from fat.  PLA meshes 
with micro to nano sized fibres containing 1%, 5% and 10% estradiol were constructed  and 
used for in vitro and in vivo experiments.  
Interventions 
The angiogenic potential of the fibrous meshes was evaluated using an in vivo 
chorioallantoic membrane (CAM) and an in vitro chick aortic arch assays.  
Measurements 
Estradiol release was measured fluorimetrically.  The effect of fibrous meshes on 
proliferation and extracellular matrix (ECM) production of ADMSC was assessed by 
immunohistology.  Mechanical properties were tested using a tensiometer.  
Results and limitations 
The ultrastructure of the mesh was not affected by the inclusion of estradiol and mechanical 
properties were only slightly modified.  Estradiol was released from PLA meshes over a 5-
month period. ADMSCs cultured on estradiol-releasing PLA meshes produced more ECM 
involving collagen I, III and elastin.  Estradiol-releasing meshes doubled new blood vessel 
formation in the CAM assay (p= 0.001) and outgrowth of pro-angiogenic cells in the aortic 
arch assay (p= 0.001).  Further studies in longer term animal models are required to confirm 
these results. 
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Conclusion 
Estradiol releasing PLA meshes increase ECM production and stimulate angiogenesis. As 
such, they are promising candidate materials to be used in pelvic floor repair and to improve 
the initial healing phase of a repair material following implantation.   
Patient summary 
In this study we designed a tissue engineered material to be used to support weakened 
pelvic floor tissues in women to avoid the complications associated with current surgical 
mesh. Our results showed that this material can stimulate new blood vessel formation in 
simple chick assays and tissue production in vitro. Both properties should help in integration 
of this material into patients tissues and merit further study in physiologically relevant 
animal models.   
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1. Introduction 
In the 1990s, Petros et al reported  the implantation of PPL mesh tapes to treat stress 
urinary incontinence (SUI) 1. Following this, larger areas of mesh were used to repair pelvic 
organ prolapse (POP), however, serious complications have now been demonstrated  in up 
to 15% of women  2 and to a lesser degree in SUI surgery 3.  The US Food and Drug 
Administration released two public health warnings related to mesh complications in 2008 
and 2011 4 and in 2016 re-classified trans-vaginal mesh devices from class II to III 5. 
Subsequently these led to a reduction in the number of trans-vaginal mesh surgeries 
performed for POP from 27% to 2% 6, with a more modest decline in the number of mid-
urethral tapes inserted to treat SUI. Instead, there appears to be an increase in the number 
of no- mesh surgeries such as autologous fascia sling operations 7.  
PPL devices evolved over many years from an initial metal wire mesh 8 to the current 
monofilament, macroporous mesh 9.  PPL mesh was not designed nor evaluated for safety in 
the pelvic floor prior to its introduction.  The mechanical properties, microbial flora and 
vascularization status of paravaginal tissues are very different to that of the abdomen. 
Recent data has demonstrated site-specific responses to implanted PPL mesh; contraction 
and exposure of the mesh occurred following trans-vaginal implantation in sheep, while no 
complications were demonstrated following  abdominal implantation over 12 months 10.  
Furthermore, PPL mesh undergoes an M1 (proinflammatory) macrophage response, 
characterized by expression of pro-inflammatory cytokines, which leads to a vigorous 
foreign body reaction 11. 
Materials that are specifically designed for implantation into the pelvic floor are urgently 
required 12.  In exploring several candidate materials, we identified electrospun poly-L-lactic 
acid (PLA) mesh as a material, which possess mechanical properties more closely related to 
those of healthy paravaginal tissues 13 and it induces an M2 macrophage response 
associated with constructive remodelling 11.  Electrospun PLA may therefore lead to better 
integration during the initial healing phase following implantation, whilst providing 
appropriate structural support for tissues.   
A well vascularized wound bed is crucial to achieve rapid integration of materials following 
implantation. Clinical studies report a decrease in vaginal blood flow in postmenopausal 
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women, which improves significantly after estrogen replacement 14. 17-ɴĞstradiol plays a 
vital role in maintenance of normal structure and function of pelvic tissues. It is an inhibitor 
of matrix metalloproteinases 15 and stimulates neo-collagen synthesis 16 and directly 
stimulates vascular endothelial cells through the estrogen receptor 17.  
A potential solution to improving the angiogenic potential of repair devices is to incorporate 
pro-angiogenic drugs into materials 18. In this respect estradiol is an attractive agent as it has 
a known safety profile and is in clinical use for this purpose .The aim of this study was to 
develop an estradiol-releasing electrospun mesh of PLA  ,evaluating its ability to support  
new tissue formation  and to stimulate neovascularization to improve the integration of 
materials into the wound bed  for urogynaecological applications.     
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2. Materials and Methods 
2.1. Electrospinning 
Poly-L-lactic acid (Goodfellow, Cambridge, UK) at 10% (wt/v) was dissolved in 
dichloromethane (DCM).  17-ɴ estradiol (Sigma-Aldrich) was dissolved in DCM added at 1%, 
5% and 10% by mass of polymer to produce colourless solutions.  20mls of polymer 
solutions were loaded into syringes fitted with 21G needles, placed into a syringe pump 
(GenieTMPlus, Kent Scientific, USA), and delivered at 40ʅů ?ŵŝŶƉĞƌƐǇƌŝŶŐĞ ?Random 
microfibres were created at an accelerating voltage of 17kV DC and collected on an 
aluminium foil covered earthed mandrel rotating at 300rpm. 
2.2. Scanning Electron Microscopy (SEM) 
Samples were mounted on 12.5mm stubs and sputter coated with 25nm of gold (Edwards 
sputter coater S150B, Crawley, England).  SEM (Philips/FEI XL-20 SEM; Cambridge, UK) was 
performed at an accelerating voltage of between 10-15 kV and a SPOT size between 2 and 3. 
Fibre diameter and pore size were measured using ImageJ software (National Institute of 
Health) 19.   
2.3. Release of estradiol from the fibrous meshes 
Meshes were cut to 15mm2, weighed and incubated in 1ml/well of Phosphate buffered 
saline (PBS).  The estradiol concentration released from each of the 3 mesh groups (10mg 
(1% wt/vol), 50mg (5% wt/vol) and 100mg (10% wt/vol)) over 5 months was measured 
fluorimetrically (Kontron SFM 25 spectrofluorimeter) Ăƚʄex ? ? ?Ŷŵ ?ʄem310nm against 
solutions of known concentration (n=6 per group).  Fresh PBS was replaced after each 
sample was removed.   
2.4. Culture of Adipose-derived mesenchymal stem cells (ADMSC) on meshes  
ADMSC were cultured from human subcutaneous fat as described previously 13, donated 
under an HTA research tissue bank license (08/H1308/39).  Cells were cultured in ƵůďĞĐĐŽ ?Ɛ
Modified Eagles medium (DMEM) supplemented with 10% (v/v) fetal calf serum (FCS) 
(Advanced Protein Products, Brierley Hill, UK) ? ?ŵDŐůƵƚĂŵŝŶĞ ? ? ? ? ? ?ʅŐ ?ŵ>ĂŵƉŚŽƚĞƌŝĐŝŶ ?
 ? ? ?/h ?ŵ>ƉĞŶŝĐŝůůŝŶĂŶĚ ? ? ?ʅŐ ?ŵ>ƐƚƌĞƉƚŽŵǇĐŝŶ(Gibco Invitrogen, Paisley, UK).  
Meshes were cut to 15mm2 and sterilized in 70% ethanol.  500,000 passage 3 ADMSC were 
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seeded per mesh and samples cultured for 2 weeks at 37oC, 5% CO2. The metabolic activity 
of seeded ĐĞůůƐǁĂƐƋƵĂŶƚŝĨŝĞĚďǇůĂŵĂƌůƵĞ ?(Sigma-Aldrich, Dorset, UK) assay at days 7 
and 14, as described previously 19.   
2.5. Assessment of ability of ADMSC to proliferate and produce extracellular matrix on estradiol 
releasing fibrous meshes  
Samples were fixed with paraformaldehyde after 2 weeks of culture and stained with 1ml of 
 ?ŶŐ ?ŵůŽĨ ?഻ ? ?-diamidino-2-phenylindole dihydrochloride ((DAPI) Gibco Invitrogen, Paisley, 
UK).  After incubating with bovine serum antigen (BSA), following primary antibodies were 
added (all AbD Serotec, Oxford, UK) and incubated for 1 hour:  100µl of 20ʅg/ml each of 
goat anti-human collagen I and collagen III and 100µl of 0.25mg/ml rabbit anti-human alpha 
elastin at concentrations of 20ʅg/ml, 20ʅg/ml and 0.25mg/ml, respectively in BSA. 
Secondary antibodies were subsequently added and included 100µl of 20ʅg/ml FITC labelled 
rabbit anti-goat IgG for collagen I/III and  100µl of 20ʅg/ml FITC labelled goat anti-rabbit IgG 
for elastin and incubated for 1 hour.   
 DAPI stained nuclei and FITC labelled matrix components were imaged using a fluorescent 
microscope (Axon ImageXpressTM, Molecular Devices Limited, Union City, CA) by switching 
ďĞƚǁĞĞŶĨŝůƚĞƌƐĨŽƌW/ ?ʄex ? ? ?Ŷŵ ?ʄem ? ? ?Ŷŵ ?ĂŶĚ&/d ?ʄex ? ? ?Ŷŵ ?ʄem515nm).   
Total collagen production was measured by Sirius Red staining as described previously using 
a 0.1% solution of Sirius Red F3B in saturated picric acid 19.    
2.6.   Assessment of effects of estradiol on differentiation capacity of ADMSC 
ADMSCs at passage 3 were cultured with 15mm2, weight matched sections of either 
estradiol-releasing or control PLA meshes in DMEM (n=6).  After 24 hours, media was 
replaced with specific induction medium and cultured for 3 weeks.  Adipogenic and 
osteogenic induction media contained the following supplements in addition to above 
defined DMEM:  1 µM dexamethasone, 0.5 mM methyl-isobutylxanthine, 10 µg/mL insulin 
and l00 µM indomethacin for adipogenic media and 10 nM dexamethasone, 50 µg/mL 
ascorbate-2-phosphate and 2 mM b-glycerophosphate for osteogenic media.   
Cells were fixed and stained with Oil Red O and Alizarin Red for adipogenic and osteogenic 
phenotypes, respectively. Counter staining was performed using haematoxylin.  Histological 
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differences were assessed blindly by 6 post-doctoral researchers.  All reagents were from 
Sigma-Aldrich, Dorset, UK.  
2.7. Assessment of effect of estradiol on mechanical properties of fibrous meshes 
Meshes were cut into 5mm x 10mm sections and clamped into a tensiometer (BOSE 
Electroforce Test Instruments, MN) using a 22N load cell and a ramp test at a rate of 
0.1mm/sec. Results were standardized by width and thickness of materials (N/mm2).  Tests 
were performed both before and after 7 days of ADMSC culture on the meshes.   
The initial linear gradient of each resulting stress vs strain ĐƵƌǀĞǁĂƐƚĂŬĞŶĂƐƚŚĞzŽƵŶŐ ?Ɛ
modulus (N/mm2), while the ultimate tensile strength (UTS) was taken as the force per area 
of sample at break/maximal point.  Both values were compared to data published for 
paravaginal tissues of healthy premenopausal patients 20.   
2.8. Assessment of angiogenic potential  of estrogen releasing meshes  
Angiogenesis was assessed using an ex ovo chick chorionic allantoic membrane (CAM) and 
an in vitro chick aortic arch assay.  Pathogen-free fertilized white leghorn chicken eggs 
(Gallus gallus domesticus) were obtained from Henry Stewart Co. (UK). Care was consistent 
with the Home Office, UK guidelines. Embryos were cultured using an ex ovo (shell less) 
method 21. Embryos were transferred into a petri dish on embryonic development day (EDD) 
3 and maintained in a humidified incubator at 38°C between EDDs 3 to 14. Embryo survival 
was assessed daily.  
The ex ovo CAM assay 
Meshes were cut into 6.5mm diameter circles using an Epilog Laser Cutter (Clevedon, UK) 
and sterilized under UV light. At EDD 8, two meshes were placed on the CAM surface.  At 
EDD 14, images of meshes and surrounding CAM area were taken with a digital microscope. 
After imaging, 0.1mL of a 20% solution of Lens culinaris agglutinin [LCA (Vector 
Laboratories)] was injected into the circulation using a 30G hypodermic needle to 
fluorescently label intraluminal endothelial cells. Embryos were sacrificed and meshes were 
removed from the CAM surface.  Angiogenesis was quantified by counting all discernible 
blood vessels traversing a 1mm annulus about the 2mm imaginary circle drawn around the 
mesh 22.   
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Chick aortic assay 
Embryos were sacrificed on EDD 14, the aortic arch removed and cut into 1mm rings under 
a stereomicroscope.  Aortic rings were embedded in 50µL of Matrigel® (Basement 
Membrane Matrix, Corning®) and cultured in Minimum Essentials Media supplemented with 
 ? ? ?A?&^ ? ? ?ƵŶŝƚƐ ?ŵ>ƉĞŶŝĐŝůůŝŶĂŶĚ ? ?ʅŐ ?ŵ>ƐƚƌĞƉƚŽŵǇĐŝŶ (GIBCO, Carlsbad, CA). Rings 
were co-cultured with meshes using an insert (Greiner Bio-One GmbH).  Endothelial sprout 
length was observed under an inverted microscope from day 5. Endothelial cells were 
characterized by immunofluorescence staining with 10 µg/ ml Isolectin B4 (Vector 
Laboratories, Burlingame, USA).   
Histology  
Meshes and surrounding CAM were fixed with paraformaldehyde, and embedded in 
freezing medium. 6µM sections were taken using a cryostat (Leica CM1860UV, Leica, 
Germany). Slides were stained with DAPI and observed under an epifluorescence 
microscope (Olympus, Japan).   
2.9. Statistics 
 Statistical differences between two group means were analysed using Student ?Ɛ T test when 
the data was normally distributed and with Mann Whitney U test otherwise. Survival of the 
chick embryos was analysed with the Kaplan Meier method.  A p value of <0.05 was 
considered statistically significant.    
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3. Results 
3.1. Effect  of estradiol on mesh ultrastructure  
There was no significant difference between the fibre diameter and pore size of PLA versus 
estradiol-releasing PLA meshes (0.65±0.30 µm vs 0.71±0.28 µm [p=0.47] and 4.26±2.29 µm 
vs 4.25±2.04 µm [p= 0.98], respectively) as shown in Figure 1. The lipophilic estradiol could 
effectively be loaded directly into the fibres of the PLA as demonstrated by the absence of 
visible drug crystals on the fibres ?ƐƵƌĨĂĐĞ ? 
3.2. Release of estradiol from meshes over 5 months 
The cumulative release of estradiol increased for each time-point, until no further estradiol 
was released as demonstrated in Figure 2.  A burst release of between 40- 50% of the drug 
was observed in the first 14 days.  The cumulative release of estradiol was roughly 
proportional to the concentration of estradiol loaded-the percentage release over 133 days 
was of the order of 1.5 to 2.5% -calculated to be  2.5%, 1.4% and 2.45% of the initial 
estradiol present in the polymer solution for the 10mg, 50mg and 100mg estradiol meshes, 
respectively.  
3.3 Effect of estradiol releasing meshes on differentiation capacity of ADMSC 
Culturing ADMSC in specific induction media resulted in cellular differentiation over 3 
weeks, including the formation of lipid vesicles for ADMSC cultured in adipogenic medium 
and the presence of calcium for cells cultured in osteogenic medium (Figure 3).  There were 
no significant differences in cell morphology, lipid vesicles or calcium content between 
control and estradiol-releasing meshes, as assessed using blind scoring.   
3.4 Effect of estradiol on metabolic activity and extracellular matrix production of ADMSCs  
Figure 4A demonstrates an increase in metabolic activity from 7 to 14 days for cells cultured 
on both estradiol and control meshes, with a greater increase seen for cells cultured on 
estradiol meshes (p<0.01).  ADMSCs cultured on estradiol meshes for 14 days produced a 
greater proportion of total collagen than cells cultured on control meshes (p<0.001) as 
demonstrated in Figure 4B.  Figure 4C shows a greater proportion of collagen I and III and 
elastin from culture of ADMSC on estradiol meshes compared to controls, a finding which 
reaches statistical significance for collagen III and elastin as demonstrated in table 1.   
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Table 1. Quantification of extracellular matrix component expression using a blind scoring system. 
Mean ± standard deviation (SD) of 5 representative immunohistochemistry images for each of 
collagen I, collagen III and elastin as assessed by 6 blinded post-doctoral reviewers.  Scoring system 
includes 0  ? absence, 1  ? mild presence, 2  ? moderate presence, 3  ? large presence, 4  ? abundance, 
5  ? great abundance.   
 Collagen I Collagen III Elastin 
Estradiol No estradiol Estradiol No estradiol Estradiol No estradiol 
Mean 4.0 3.50 2.67 1.17 2.83 1.33 
SD 0.63 0.55 0.52 0.41 0.52 0.41 
P value 0.1739 0.0002 0.0002 
 
3.5 Effect of estradiol on the mechanical properties of meshes 
Figure 5A demonstrates that estradiol-releasing meshes ƐŚŽǁĂzŽƵŶŐ ?ƐDŽĚƵůƵƐĐůŽƐĞƌƚŽ 
the values of healthy native fascia. After 2 weeks of cell culture, both meshes become more 
elastic, however estradiol-releasing meshes were significantly stiffer (p<0.01) than control 
meshes. Figure 5B demonstrates that estradiol-releasing meshes are significantly stronger 
than controls, both before and after 2 weeks of cell culture.  Of note, the UTS of control 
meshes decreases after 14 days of cell culture, while the UTS of estradiol-releasing meshes 
increases. 
3.6  Effect of estradiol on the angiogenic properties of PLA meshes 
The CAM assay demonstrates at least double the number of blood vessels growing towards 
the estradiol meshes compared to controls over 7 days (mean vessel count: 25.0 (±5.29) and 
10.67 (±2.64) respectively, p<0.001 as shown in Figure 6A and B).  Estradiol did not affect 
embryo survival rates (Figure 6C).    
Estradiol-releasing PLA meshes induced longer and denser endothelial sprouts when co-
cultured with chick aortic rings (Figure 7A).  Figure 7C demonstrates a sprout length/radius 
of 1.6 (±0.51) and 1.0 (±0.44) for estradiol-releasing and control meshes respectively 
(p=0.01) (Figure 7C).   
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Host tissues infiltrated into each mesh to a similar degree (Figure 8).  There was an 
increased number of blood vessels (stained with fluorescent angiography) in the CAM tissue 
adjacent to and in- between the fibres of the estradiol-releasing meshes compared to 
controls. After incubation in the in vivo environment for 7 days, meshes contracted to a size 
of 43.2% (±1.1)  and 41.2% (±8.3) of their original area for estradiol and control meshes, 
respectively (p=0.48).  
13 
 
4 Discussion 
Ideally biodegradable repair materials should ŝŶƚĞŐƌĂƚĞǁĞůůŝŶƚŽƚŚĞƉĂƚŝĞŶƚ ?ƐƚŝƐƐƵĞƐ and be 
strong enough to provide structural support, while regeneration of host tissues over time 
eventually assumes this load bearing function.  
In this study we demonstrate that incorporation of estradiol into the fibres of an 
electrospun PLA mesh do not significantly alter the overall microstructure of the mesh. The 
estradiol releasing PLA mesh was more elastic and stronger compared to control PLA 
meshes after culturing with cells in vitro  for 14 days.  This can be attributed to the 
stimulatory  effect of estradiol on cells and/ or direct plasticizing effect of estradiol, as there 
ŝƐĂĚŝĨĨĞƌĞŶĐĞŝŶzŽƵŶŐ ?ƐŵŽĚƵůƵƐĂŶĚƵůƚŝŵĂƚĞƚĞŶƐŝůĞƐƚƌĞŶŐƚŚďĞĨŽƌĞĐƵůƚƵƌŝŶŐ ? Tissue 
integration was assessed in this study through the interaction of cells in vitro with the mesh 
and the ability of the mesh to stimulate angiogenesis using in vivo and in vitro models. For 
the former, ADMSC were selected as a representative cell source, capable of undertaking a 
range of phenotypes.  Estradiol was released over a five-month period in a dose-dependent 
manner. Meshes consisted of random micro/ nano-fibres with a range of pore sizes up to 
10µm. While porosity influences the ease of cell infiltration into the mesh, our previous 
studies with electrospun PLA implanted in rats 23 and rabbits 11 demonstrate a rapid 
integration of host tissues into these with an M2 macrophage (tissue remodelling) response.  
Several assessments of non-degradable polypropylene meshes in dogs 24, sheep 10, rhesus 
macaque 25 and humans 26 demonstrate sustained chronic inflammation. Biodegradable PLA 
meshes last intact for at least one year when implanted in rat models 23. In the current study 
we demonstrate that inclusion of estradiol improved the ability of ADMSCs to stimulate new 
ECM production in vitro including collagen I, III and elastin. 
The most critical feature of this estradiol-releasing PLA mesh is the significant increase seen 
in the number and density of blood vessels and integration of tissues into this material 
when implanted into the CAM assay.  The CAM assay is an established method for the in 
vivo evaluation of angiogenesis, which allows direct visualization of the newly forming 
vessels into a biomaterial 27.   
An estradiol releasing electrospun mesh has previously been described for use as a wound 
care product in post-menopausal women, where the anti-inflammatory properties of 
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estradiol were utilized 28. Estradiol has  been demonstrated to stimulate endothelial cells to 
produce VEGF when released from a collagen based mesh 29. Here we demonstrate for the 
first time that estradiol released from an electrospun mesh dramatically stimulates new 
blood vessel formation in and around the material.  Although we have designed this 
material for use in pelvic floor repair, it could have wider applications in all areas of tissue 
engineering as a pro-angiogenic mesh.    
The promising results obtained in this study will now need to be confirmed in physiologically 
relevant animal models to evaluate the potential for progressing to the clinic. Animal studies 
will particularly be helpful to evaluate the inflammatory response to estradiol releasing PLA 
meshes as the chick embryo used in this study does not have a mature immune system. Also 
the size of the mesh material used in our experiments are much smaller than that would be 
required in  clinical practice and materials need to be implanted under load for many 
months to assess their mechanical properties and longer term tissue integration.     
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Reviewer 1 
We thank the reviewer for evaluating our work.  
 
Reviewer 2 
1. this study lacks the final experiment of surgical implantation in mammals of PLA meshes 
loaded with oestrogen and ADSCs. This is particularly important because ADSCs may exert 
protection on lesioned tissues, potentiate differentiation of resident stem cells or even 
differentiate in other cell types, all of which could impact on the beneficial effects on blood 
vessel formation.   
 
Our reply: 
We thank the reviewer for this comment. The need to confirm these promising results in an 
animal model has now been added to the discussion as a limitation of this study. In this study  
the ADSCs  were used to assess the ability of the scaffolds to allow cell penetration as we 
hope would occur in vivo.. Thus we do not, in this study  propose implantation of our 
scaffolds with ADSCs on them. 
It is a possibility for the future and we have just started to look at this possibility but 
recognise that it will take significant work and will be a bigger regulatory hurdle to overcome 
than  implanting a membrane releasing a known pro-angiogenic hormone already in clinical 
use. 
The word limit of the manuscript prevents us going into this anything other than a cursory 
fashion which we now do in the discussion. 
 
2. I suggest reviewing the writing of the manuscript. At some points, it still reads more like a 
draft than the final version. For example, the dilution of the primary antibodies against 
collagen and elastin are not referred nor if the intensity of immunolabelling of elastin was 
evaluated. Also, the legends could give a bit more detail. 
 
Our reply: 
We thank the reviewer for this comment and the manuscript has now been revised and 
further detail particularly in the legends have been added. The dilution of primary antibodies 
are also added together with more detail on intensity of immunolabelling of collagen I, III and 
elastin.   
 
 
3. Lastly, I assume red arrows are pointing to blood vessels as it not indicated in the legend nor 
the magnification allows the identification of capillaries, arterioles or venules. 
 
Our reply: 
We apologise for this. The legend is now modified accordingly. The main point of 40X H&E 
images was to demonstrate the ability of the scaffolds to allow ingrowth of small blood 
vessels  in-between the fibres of the scaffolds. Higher magnifications make it very hard to 
focus on a single plane to demonstrate either the blood vessels or the PLA fibres, which does 
not show our point. That is why we need this  image as it is but we have added detail to the 
legend. 
 
reply to reviewers comments
Click here to view linked References
  
Reviewer 3 
1. they do not describe in M&M how Estradiol is bound/incubated into mesh, which is I think an 
essential step to include (I do not know if this is because of patents). 
 
Our reply: 
We thank the reviewer for this comment. This information is now added to the text in the 
results section.  Briefly, since estradiol it is a highly lipophilic steroid and it dissolves well in 
the polymer solution, it can be loaded effectively into the fibres of the electrospun PLA. In 
other words we have electrospun a drug/ polymer blend.  
 
2. Mesh is not investigated in an animal model, which I consider a limitation of this study. 
 
Our reply: 
We agree with the reviewer. This point is added to the discussion as a limitation of the study 
and something that is the next logical step to achieve.  
 
3. 'It appears that we are now back to a pre- mesh era with some important lessons to be 
learned. '  This is a very incorrect statement. There is a lot of room for improvement, but the 
amount of sling surgery performed is standard care for SUI. We are perhaps more careful 
who we select for mesh surgery. On the other hand you could state that tissue engineering 
has so far not produced any widely accepted, commercially available alternative. 
 
Our reply: 
We thank the reviewer for this comment. This point has been revised in the text.   
 
 
4. M&M ____Please include how Estradiol is incorporated into/onto the mesh. 
 
Our reply: 
We thank the reviewer for this comment. This information is now added to the manuscript . 
Essentially  Estradiol is loaded directly into the fibres of the PLA as we spin it. This is possible 
because of the lipophilic nature of this steroid so it can go into an organic solvent readily. 
 
5. There appears to be considerable contraction of the mesh in figure 6. Has diameter of 
scaffolds decreased over time? 
 
Our reply: 
We thank the reviewer for this careful observation.  Yes, the scaffolds contracted to nearly 
40% of their original surface area as the scaffold was infiltrated with new tissue over 7 days 
in vivo. This point is now added to section 3.6  with exact figures. 
     
6. Can authors explain the different release % between Estradiol meshes (the 50 mg mesh is 
quite a bit lower than the others. 
 
Our reply: 
The release of Estradiol from electrospun PLA scaffolds is both diffusion and degradation 
dependent. In other words, we  see a burst release of Estradiol due to the presence of non-
incorporated drugs in the surface together with a more sustained/ gradual release of small 
amounts of Estradiol over a longer period of time as the scaffolds degrade.  
The rate of release was broadly proportional to the amount of drug present in the scaffold. 
The small difference in percentage release calculated for the 50 mg scaffold we suggest is not 
significant in the overall scheme of things - for the 3 scaffolds the range of release was from 
1.4% to 2.5%- we have altered the text slightly to indicate the range of release  ? we do not 
want to put undue emphasis on there being less release from the 50 mg compared to other  
scaffolds.  Figure 2 shows that the cumulative release over time was much as one would 
expect it taking into account the amount of estradiol loaded into each scaffold. 
  
7. Figure 5: Can Authors explain how Estradiol appears to influence tensile strength before cell 
culturing (Young's Modulus ) compared to control?? 
 
Our reply: 
The reviewer has rightly raised this point. The only possible explanation we can suggest  is 
that estradiol might be acting as a plasticizer when incorporated into the fibres of the 
electrospun PLA which could thaŶĐŚĂŶŐĞƚŚĞzŽƵŶŐ ?ƐŵŽĚƵůƵƐĂŶĚƵůƚŝŵĂƚĞƚĞŶƐŝůĞƐƚƌĞŶŐƚŚ
of the scaffolds. This point is now mentioned in the discussion.  
 
8. Also I would like a comment in the discussion concerning the quite drastic decrease in 
N/mm2 after 14 days of culturing (below normal facia values). Does this further decrease 
after 14d? This has potential severe implications on the applicability of this mesh in patients 
(you need mesh that gives support for much longer periods then 14d). There is no mention of 
any of this potential severe limitation in the discussion.     
 
Our reply: 
We thank the reviewer for this important comment.  The ultimate tensile strength of PLA 
scaffolds decreased significantly 14 days after culturing them with ADSCs in vitro.  The main 
point we wanted to demonstrate was that presence of estradiol within the PLA scaffolds 
prevented this unwanted effect on the mechanical properties in vitro. This could be due to 
the production of new extracellular matrix produced by ADSCs that might have replaced 
some of the functionality of the ECM and/ or it might be due to the plasticizing effect of 
estradiol on scaffolds.  
For PLA only scaffolds, the reviewer is right to think that the ultimate tensile strength might 
further degrade after 14 days with cells -however this 2 week snapshot is only part of the 
picture. As we acknowledge in the discussion the next logical step for this work is to progress 
it into an in vivo model where the scaffolds need to be implanted for long enough ( probably 
3 months as we have previously done in rabbit experiments working with colleagues in 
Leuven ) to be able to comment sensibly on the mechanical properties of the scaffolds after 
several months of implantation. Even this is not ideal- we really need to be able to implant 
scaffolds for at least a year in a large animal model such as a sheep. As the reviewers will be 
aware this is not a trivial experiment but the very promising results we have found from this 
in vitro study now suggest that we should seek the funding and resources to take this 
material into a larger animal experiment and run it for a much longer time. 
When doing such animal experiments the scaffolds would be implanted without cells and the 
impact of including oestradiol on the tissue integration of the scaffolds and their mechanical 
properties would be assessed. 
 
 
 
9. Resolution of images figure 7 B is poor and could use a higher magnification to clearly show 
content. Also images for figure 3 and 7B are too dark to interpret 
 
Our reply: 
We have now corrected the brightness of the figures 3 & 7 and changed figure 7B. 
 
10. Discussion. 
There is no critical discussion on limitations of the study.: examples: 1) The further need to 
investigate the mesh in an animal model. 2) That an animal model is perhaps better to 
investigate inflammatory responses. 3) That only small mesh sizes has been investigated and 
not larger ones that would be needed for clinical use. 4) The use of ADMSC 5) what are the 
current prospects for using these meshes in the clinical studies, have they been done /how 
does thŝƐŵŽĚĞůƌĞůĂƚĞƚŽƚŚĞƐĞ ? 
 
Our reply: 
We thank the reviewer for this comment. A paragraph about the limitations of our study and 
where it needs to go next to be able to comment on tissue integration and mechanical 
properties has now been added to the discussion.  
Figures 
 
 
Figure 1. Evaluation of the microstructure of the electrospun PLA only meshes and estradiol releasing 
PLA meshes by scanning electron microscopy. Micro- nano sized random fibres and the  microporous 
structure of the mesh can be observed. Histograms on the right demonstrate distribution of fibre 
diameters and pore sizes in both meshes. Scale bars represent 10 µm. 
revised figures
 Figure 2. Cumulative release of estradiol from 3 different estradiol releasing meshes over 133 days in 
a concentration dependent manner. Estradiol is gradually released from meshes after an initial burst 
release in the first 14 days.  Measurements done  using a spectrofluorometer (n=6±SEM). 
 
Figure 3.  Effect of estradiol releasing meshes on the differentiation capacity of adipose derived 
mesenchymal stem cells (ADMSC).  ADMSCs cultured either in DMEM, adipogenic media or 
osteogenic media, stained with haematoxylin and Oil red O (for lipid vesicles) or Alizarin red (for 
calcium).  Scale bar represents 50µm.   
 Figure 4.  Extracellular matrix production by ADSC cultured on Estradiol releasing PLA meshes 
compared to PLA only meshes. (A) Cell metabolic activity of ADSC cultured on control and estradiol 
releasing PLA meshes as measured by AlamarBlue assay with absorbance measured at 570nm using 
plate reading colourimeter.  (n=6 ±SEM). **p<0.01. (B)  Total collagen production at day 14 as 
measured by Sirius red assay with absorbance measured at 490nm using plate reading colourimeter.  
(n=6 ±SEM). ***p<0.001. (C) Fluorescent microscopy images of extracellular matrix components 
produced by ADSC after 14 days of culture.  Collagen I & III (green), elastin (red) and cells (blue).  Scale 
bar represents 100µm.   
 
 
  
 
Figure 5.  The effect of estradiol on the strength of the meshes assessed in the presence of ADMSCs. 
 ?zŽƵŶŐ ?ƐDŽĚƵůƵƐŽĨĐŽŶƚƌŽůĂŶĚĞƐƚƌĂĚŝŽůƌĞůĞĂƐŝŶŐW>meshes, before and after 14 days of cell 
culture with ADSC.  Area between dashed lines represents values for healthy native fascia [18].  
N=6±SEM, **p<0.01.   
A 
B 
B.  Ultimate Tensile Strength of control and estradiol releasing PLA meshes, before and after 14 days 
of cell culture with ADSC.  The area between the dashed lines represents values for healthy native 
fascia [18].  N=6±SEM, ***p<0.001.   
 
 
Figure 6.  Angiogenic potential of estradiol releasing PLA meshes compared to PLA only meshes, day 
14 on chicken chorioallantoic membrane (CAM) assay. A normal distribution of blood vessels was 
observed when the control PLA mesh was placed on the CAM. With the estradiol releasing mesh 
newly formed blood vessels can be seen to radiate towards the mesh in a spoke- wheel pattern (A). 
The mean vessel count of estradiol releasing meshes was double that of the PLA meshes (B) and the 
embryo survival rate was the same between the two groups (C).   (Scale bars represent 3mm). 
 Figure 7.  A)  Evaluation of effect of estradiol on endothelial cell proliferation and sprouting. One 
millimetre rings from the chick aorta were embedded in Matrigel and co- cultured with PLA only 
meshes (upper row) or Estradiol releasing PLA meshes   (lower row). The extent of endothelial 
sprouting by 5 days in culture is much greater in the presence of estradiol. B) Fluorescent microscopy 
images of immunological staining.  Lectin IB4 - endothelial cells stained green, nuclear components 
stained blue (DAPI).  C) Sprout length/radius results taken from 11A, * P=0.01.  (Sjnnncale bars 
represent 50 µm). 
 
 
  
Figure 8. Histologic evaluation of tissue- mesh interface. A mild inflammatory reaction  together with 
a normal distribution of blood vessels on the CAM adjacent to the PLA mesh (upper raw) can be 
observed compared to a significantly increased number of large blood vessels in response to Estradiol 
releasing PLA mesh (lower raw) at day 14, Haematoxylen &Eosin (H&E) staining (left side). Also on 
higher magnification several small blood vessels could be observed in between the PLA fibers which 
was more abundant in the presence of Estradiol (middle). On the right endothelial cells lining all sizes 
of blood vessels appear stained Rhodamine- conjugated Lens culinaris agglutinin and cell nuclei are 
stained with DAPI.  Scale bars represent 100 µm. 
